HER2阳性乳腺癌的治疗和耐药性
Jamunarani Veeraraghavan1,2,3, Carmine De Angelis1,2, Carolina Gutierrez1,2
1Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Advances in experimental medicine and biology
|January 17, 2025
概括
HER2阳性乳腺癌治疗改善了结果,但耐药性仍然是一个挑战. 了解耐药机制对于开发新疗法来克服治疗失败至关重要.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- HER2阳性乳腺癌是侵略性的,历史上预后不佳.
- 特拉斯图祖马布和随后的HER2向疗法显著改善了患者的治疗结果.
- 治疗耐药性是HER2阳性乳腺癌管理的一个主要临床挑战.
研究的目的:
- 审查对HER2向疗法的耐药性背后的机制.
- 突出了解耐药性对于开发新型治疗策略的重要性.
- 讨论新兴的向药剂和克服耐药性的方法.
主要方法:
- 关于 HER2 向疗法和耐药机制的科学文献的综述.
- 分析涉及治疗耐药性的分子途径.
- 综合有关当前和未来治疗策略的信息.
主要成果:
- 抵抗机制包括HER受体的重新激活和下游信号通路的放松调节 (例如PI3K/AKT,RAS/MEK/ERK).
- 补偿途径 (例如,ER,其他RTK,代谢途径) 也可以驱动抵抗.
- 瘤微环境的改变有助于治疗耐药性.
- 新的向剂和方法正在调查中,以克服抵抗.
结论:
- 了解耐药性的机制基础对于有效的治疗开发至关重要.
- 针对抗性的关键驱动因素,包括瘤上皮细胞特异性和微环境相关机制,是一个有前途的战略.
- 目前正在进行的研究正在确定新的治疗漏洞和抗抗HER2治疗耐药性的药物.
更多相关视频
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.5K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
相关概念视频
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
